secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001437749-26-001500
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance
--------------------------------------------------------------------------------

- 22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.
- Among 20 cSCC patients, 14 responders; 10 complete (100% clearance), 2 major/near clear, 2 partial.
- PH-762 well tolerated with 20-fold dose escalation; safety follow-up data expected in Q2 2026.
- One Merkel cell carcinoma patient had partial response; no disease progression in any patient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926001500/0001437749-26-001500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926001500/phio20260113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer